Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNUV204
- Development stage
- Preclinical
- Lead developer
- Genuv
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
GNUV204 is a next-generation Interleukin-2 (IL-2) based biologic immunotherapy being developed by Genuv, a clinical-stage biotechnology company based in Seoul. Designed for the treatment of solid tumors, GNUV204 is engineered to overcome the limitations of traditional IL-2 therapies, specifically by minimizing severe side effects such as vascular leak syndrome and regulatory T cell-mediated immune suppression. The program has been recognized and supported by the Korea Drug Development Fund (KDDF), highlighting its potential as a differentiated candidate in the immuno-oncology space that aims to selectively activate effector immune cells for enhanced anti-tumor activity.
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on GNUV204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNUV204.